Skip to content

Released Mar 13, 2025, after the close

10-K filed Mar 13, 2025, 72 days after period end · 0001683168-25-001581

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$6.45MderivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$6,559,128—
Operating Cash Flowderived-$4,772,415N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figures
Net Income-$6.45M-$7.61M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR